CEL-SCI Corporation (CVM)

Market Cap	59.03M
Revenue (ttm)	n/a
Net Income (ttm)	-29.95M
Shares Out	54.16M
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	172,562
Open	1.130
Previous Close	1.130
Day's Range	1.080 - 1.140
52-Week Range	1.040 - 3.230
Beta	1.04
Analysts	Strong Buy
Price Target	10.00 (+817.43%)
Earnings Date	Aug 9, 2024

About CVM

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune sy...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 1, 1987
• Employees: 43
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CVM

Analyst Forecast

According to one analyst, the rating for CVM stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(817.43% upside)

Analyst Consensus: Strong Buy